ATLAS: Patient-Reported Outcomes From Phase III Study of Switch to Long-Acting Injectable Cabotegravir + Rilpivirine in Virologically Suppressed Patients

Source: 10th IAS Conference on HIV Science
Download Slideset
July 21-24, 2019; Mexico City, Mexico
97% of patients receiving long-acting injectable therapy said that they preferred it to continued daily oral ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: July 25, 2019

Acknowledgements

Provided by USF
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings